These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

418 related articles for article (PubMed ID: 30891617)

  • 1. Innate immune regulatory networks in hepatic lipid metabolism.
    Bai L; Li H
    J Mol Med (Berl); 2019 May; 97(5):593-604. PubMed ID: 30891617
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatic lipid accumulation: cause and consequence of dysregulated glucoregulatory hormones.
    Geisler CE; Renquist BJ
    J Endocrinol; 2017 Jul; 234(1):R1-R21. PubMed ID: 28428362
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FBXW7 suppresses HMGB1-mediated innate immune signaling to attenuate hepatic inflammation and insulin resistance in a mouse model of nonalcoholic fatty liver disease.
    Zhang C; Chen F; Feng L; Shan Q; Zheng GH; Wang YJ; Lu J; Fan SH; Sun CH; Wu DM; Li MQ; Hu B; Wang QQ; Zhang ZF; Zheng YL
    Mol Med; 2019 Jun; 25(1):29. PubMed ID: 31215394
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emerging Molecular Targets for Treatment of Nonalcoholic Fatty Liver Disease.
    Chen Z; Yu Y; Cai J; Li H
    Trends Endocrinol Metab; 2019 Dec; 30(12):903-914. PubMed ID: 31597607
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 'Micro-managers' of hepatic lipid metabolism and NAFLD.
    Liu W; Cao H; Yan J; Huang R; Ying H
    Wiley Interdiscip Rev RNA; 2015; 6(5):581-93. PubMed ID: 26198708
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of Innate Immune Signaling in Non-Alcoholic Fatty Liver Disease.
    Cai J; Zhang XJ; Li H
    Trends Endocrinol Metab; 2018 Oct; 29(10):712-722. PubMed ID: 30131212
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oxidized LDL at the crossroads of immunity in non-alcoholic steatohepatitis.
    Houben T; Brandsma E; Walenbergh SMA; Hofker MH; Shiri-Sverdlov R
    Biochim Biophys Acta Mol Cell Biol Lipids; 2017 Apr; 1862(4):416-429. PubMed ID: 27472963
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular mechanisms of hepatic lipid accumulation in non-alcoholic fatty liver disease.
    Ipsen DH; Lykkesfeldt J; Tveden-Nyborg P
    Cell Mol Life Sci; 2018 Sep; 75(18):3313-3327. PubMed ID: 29936596
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of farnesoid X receptor in hepatic steatosis in nonalcoholic fatty liver disease.
    Xi Y; Li H
    Biomed Pharmacother; 2020 Jan; 121():109609. PubMed ID: 31731192
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Non-Alcoholic Fatty Liver Disease.
    Engin A
    Adv Exp Med Biol; 2017; 960():443-467. PubMed ID: 28585211
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Innate Immune Signaling in Nonalcoholic Fatty Liver Disease and Cardiovascular Diseases.
    Cai J; Xu M; Zhang X; Li H
    Annu Rev Pathol; 2019 Jan; 14():153-184. PubMed ID: 30230967
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Free radical biology for medicine: learning from nonalcoholic fatty liver disease.
    Serviddio G; Bellanti F; Vendemiale G
    Free Radic Biol Med; 2013 Dec; 65():952-968. PubMed ID: 23994574
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Computational Model of Hepatic Energy Metabolism: Understanding Zonated Damage and Steatosis in NAFLD.
    Ashworth WB; Davies NA; Bogle ID
    PLoS Comput Biol; 2016 Sep; 12(9):e1005105. PubMed ID: 27632189
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Disturbed Vitamin A Metabolism in Non-Alcoholic Fatty Liver Disease (NAFLD).
    Saeed A; Dullaart RPF; Schreuder TCMA; Blokzijl H; Faber KN
    Nutrients; 2017 Dec; 10(1):. PubMed ID: 29286303
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Downregulation of miR-192 causes hepatic steatosis and lipid accumulation by inducing SREBF1: Novel mechanism for bisphenol A-triggered non-alcoholic fatty liver disease.
    Lin Y; Ding D; Huang Q; Liu Q; Lu H; Lu Y; Chi Y; Sun X; Ye G; Zhu H; Wei J; Dong S
    Biochim Biophys Acta Mol Cell Biol Lipids; 2017 Sep; 1862(9):869-882. PubMed ID: 28483554
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Allyl isothiocyanate ameliorates lipid accumulation and inflammation in nonalcoholic fatty liver disease
    Li CX; Gao JG; Wan XY; Chen Y; Xu CF; Feng ZM; Zeng H; Lin YM; Ma H; Xu P; Yu CH; Li YM
    World J Gastroenterol; 2019 Sep; 25(34):5120-5133. PubMed ID: 31558861
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Berberine improves glucogenesis and lipid metabolism in nonalcoholic fatty liver disease.
    Zhao L; Cang Z; Sun H; Nie X; Wang N; Lu Y
    BMC Endocr Disord; 2017 Feb; 17(1):13. PubMed ID: 28241817
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lipid oxidation products in the pathogenesis of non-alcoholic steatohepatitis.
    Bellanti F; Villani R; Facciorusso A; Vendemiale G; Serviddio G
    Free Radic Biol Med; 2017 Oct; 111():173-185. PubMed ID: 28109892
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular mechanisms of metabolic associated fatty liver disease (MAFLD): functional analysis of lipid metabolism pathways.
    Badmus OO; Hillhouse SA; Anderson CD; Hinds TD; Stec DE
    Clin Sci (Lond); 2022 Sep; 136(18):1347-1366. PubMed ID: 36148775
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protective effect of quercetin on high-fat diet-induced non-alcoholic fatty liver disease in mice is mediated by modulating intestinal microbiota imbalance and related gut-liver axis activation.
    Porras D; Nistal E; Martínez-Flórez S; Pisonero-Vaquero S; Olcoz JL; Jover R; González-Gallego J; García-Mediavilla MV; Sánchez-Campos S
    Free Radic Biol Med; 2017 Jan; 102():188-202. PubMed ID: 27890642
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.